Changsha draws a new blueprint for the development of the biopharmaceutical industry, achieving 250 billion revenue by 2025

The biopharmaceutical industry is one of the key emerging strategic industries in China.
In recent years, as the disposable income of domestic residents continues to increase, health awareness has continued to increase; and the aging population has intensified, residents' demand for medicine and medical services has also continued to increase.
Growth has promoted the rapid development of the biomedical industry, and the future industry has a huge potential for development
.
In addition to a series of favorable policies issued by the state to support the development of the industry, many places are also accelerating the development of the biomedical industry
.
2021 is the first year of the 14th Five-Year Plan.
Since this year, many places have drawn up new blueprints for the future development of the local biomedical industry
.
Recently, according to the "14th Five-Year Plan" of Changsha's biomedical industry, by 2025, the total output value (revenue) of Changsha's biomedicine (including gene technology) industry will reach 250 billion yuan, and there will be about 30 listed companies
.
It is understood that in order to accelerate the high-quality development of the biomedical industry in Changsha and comprehensively enhance independent innovation and core competitiveness, at the end of 2020, the city will also issue several policies on accelerating the high-quality development of the biomedical industry.
Introduce talents, encourage bigger and stronger, encourage R&D and innovation, support market expansion, and supplementary regulations
.
The policy has been implemented on February 1, 2021, and is valid for 5 years
.
Among them, in terms of recruiting talents, the policy is clear: For the world’s top 500, China’s top 100 pharmaceutical industry, or domestic and overseas listed biomedical companies to establish a regional headquarters in Changsha and continue to operate for 1 year or more, the company’s registered capital (referring to paid-in capital) ) Will be rewarded, and the maximum reward for a single company will not exceed 5 million yuan; for the world’s top 500, China’s top 100 pharmaceutical industry or domestic and foreign listed biomedical companies in Changsha for new investment of more than 100 million yuan (inclusive) in production projects, according to 3% of the fixed asset investment in the year will be rewarded, and the maximum reward for a single project will not exceed 5 million yuan
.
In addition, for projects that authoritative experts in the field of biomedicine bring technical teams and innovation-led results into the city’s industrialization for the first time, they will be rewarded according to 5% of the actual investment in the project for that year, and the maximum reward for a single project will not exceed 5 million yuan.

.
It is reported that since 2021, Changsha City has signed 21 key biomedical projects, 11 new projects, 34 projects under construction, with a planned total investment of 20.
8 billion yuan.
With the continuous implementation of new projects, the industry has great potential for high-quality development.

.
Changsha also attaches great importance to the R&D and innovation of the biomedical industry, and provides certain policy support to related enterprises
.
For example, for innovative Chinese medicines, innovative chemical drugs, and innovative biological products, those who have completed Phase I, II, and III clinical trials will be given a one-time reward of 5 million yuan, 10 million yuan, and 15 million yuan, respectively, and those who have completed overseas clinical research.
, A one-time reward of 3 million yuan is given, and the maximum annual reward for a single enterprise is not more than 20 million; for the improved new drugs of traditional Chinese medicine, chemical drugs, and biological products, those who have completed phase I, II, and III clinical trials will be given separately A one-time reward of 2 million yuan, 4 million yuan, and 8 million yuan will be awarded.
For those who complete overseas clinical research, a one-time reward of 2 million yuan will be given, and the maximum annual reward for a single enterprise will not exceed 10 million
.
1 million yuan will be rewarded for the varieties that have completed the consistency evaluation and the production approval documents are put into production and sold; the top 100 varieties in the province that have completed the consistency evaluation and have the production approval documents will be rewarded 2 million yuan each (including the provincial awards); The top 3 nationally-evaluated varieties will be awarded 5 million yuan each (including provincial awards)
.
At the same time, it supports breakthroughs in core technology for innovative drugs and high-end medical devices that are expected to solve major clinical and market needs.
For projects that have obtained corresponding registration approvals in Changsha and implemented industrialization in the city, the total project investment is more than 100 million yuan.
Those with a total investment of less than 500 million yuan will be rewarded at 5% of the actual investment in that year, and the maximum reward for each enterprise shall not exceed 10 million yuan; for projects with a total project investment of more than 500 million yuan, the implementation of "one matter, one discussion"
.
Up to now, there are more than 1,600 biomedical (including genetic technology) companies in Changsha, including 290 companies above designated size and 17 listed companies (including IPO meetings)
.
In 2020, the total output value (revenue) of the city's biomedicine (including gene technology) industry has reached 138 billion yuan
.